A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes (NAC for HAAF)
A Randomized Double Blinded Study to Examine the Use of N-Acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
Sponsor: University of Minnesota
This PHASE1/PHASE2 trial investigates Hypoglycemia Unawareness and Type 1 Diabetes and is currently completed. University of Minnesota leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .